Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102
Brief Summary: Study Phase: 1b/2 Indication: Previously untreated subjects with unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma.

Primary Objective(s):

Part 1: To identify safe dose levels of AMG 102, up to 15 mg/kg Q3W, to combine with ECX.

Part 2 (phase 2-double-blind): To estimate with pre-specified precision the effect of the addition of AMG 102 to ECX on progression free survival (PFS).


Options:
A: Arm Label: Phase 2 Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: Cisplatin, Drug: Placebo | Arm Label: Phase 1b; Type: OTHER; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: AMG 102; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2 Arm C
B: Arm Label: Arm A, - Modified DCF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Arm Label: ARM B - Parent DCF with G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen | Arm Label: Arm C - Modifid DCF + Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab | Intervention Type: DRUG; Name: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Assigned to Arm(s): Arm A, - Modified DCF | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen; Assigned to Arm(s): ARM B - Parent DCF with G-CSF | Intervention Type: DRUG; Name: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Assigned to Arm(s): Arm C - Modifid DCF + Trastuzumab
C: Arm Label: Onartuzumab+mFOLFOX6; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluoruracil, Drug: Folinic acid, Drug: Onartuzumab, Drug: Oxaliplatin | Arm Label: Placebo+mFOLFOX6; Type: PLACEBO_COMPARATOR; Interventions: Drug: 5-Fluoruracil, Drug: Folinic acid, Drug: Oxaliplatin, Drug: Placebo | Intervention Type: DRUG; Name: 5-Fluoruracil; Assigned to Arm(s): Onartuzumab+mFOLFOX6, Placebo+mFOLFOX6 | Intervention Type: DRUG; Name: Folinic acid; Assigned to Arm(s): Onartuzumab+mFOLFOX6, Placebo+mFOLFOX6 | Intervention Type: DRUG; Name: Onartuzumab; Assigned to Arm(s): Onartuzumab+mFOLFOX6 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Onartuzumab+mFOLFOX6, Placebo+mFOLFOX6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+mFOLFOX6
D: Arm Label: Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): Ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Placebo, Ramucirumab

Answer: A